mRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.
Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability.
Through grants, international market entry support, facilitating and entering into research agreements and partnerships, mRNA Victoria delivers programs to support the development and commercialisation of mRNA research.
mRNA Victoria’s Scientific Advisory Group
mRNA Victoria is advised by a Scientific Advisory Group made up of world-leading experts from the medical research sector. The Scientific Advisory Group works in consultation with mRNA Victoria, supporting the development of the mRNA ecosystem and research in Victoria.
The members of the group are:
- Dr Amanda Caples – Victoria’s Lead Scientist and Chair of the Group
- Professor Sharon Lewin – Director, Doherty Institute
- Dr Barney Graham – Deputy Director, Vaccine Research Center, US National Institutes of Health
- Professor William Charman – Sir John Monash Distinguished Professor, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
- Professor Brendan Crabb – Director, Burnet Institute
- Professor Doug Hilton – Director, Walter and Eliza Hall Institute of Medical Research
- Professor Terry Nolan – Head, Infectious Diseases, University of Melbourne
- Professor John Carroll – Director, Monash Biomedicine Discovery Institute
- Professor Andrew Steer – Director, Infection and Immunity, Murdoch Children’s Research Institute
- Professor Ricky Johnstone – Head, Gene Regulation Laboratory, Peter MacCallum Cancer Centre
- Dr Minna-Liisa Änkö – Head, Functional RNAomics laboratory, Hudson Institute of Medical Research
mRNA Victoria’s Industry Panel
mRNA Victoria has been working with the national industry association, AusBiotech and the BioMelbourne Network to establish a panel of industry experts and service providers to complement the expertise of the SAG. The Industry Panel will comprise Victorian-based companies with relevant experience in mRNA or RNA-related manufacture, supply chain and systems support.
Development of Australia's first mRNA vaccine
mRNA Victoria is providing funding support for the Monash Institute of Pharmaceutical Sciences (MIPS) and the Doherty Institute to manufacture mRNA COVID-19 vaccines for clinical trials, due to start late 2021.
This will be Australia’s first local mRNA COVID-19 vaccine candidate to reach Phase 1 clinical trials, with preliminary results expected to be available in the first half of 2022.
The collaboration between MIPS, the Doherty Institute and mRNA Victoria reinforces the strong mRNA research sector in Victoria as well as Australia’s leading mRNA manufacturing capability.
Victoria's mRNA ecosystem
Victoria has long been the centre of Australia’s biotech and medical research ecosystem with the deepest research, therapeutic and clinical capability in the Asia-Pacific region. Victoria is the leading State in Australia for mRNA research and is adding mRNA manufacturing to its world-class biotech precinct.
Victoria is home to CSL, the second largest influenza vaccine manufacturer in the world, as well as Pfizer, Sanofi, Novartis, Merck, Bristol Myers Squibb, Aspen and GSK. 70 per cent of the top 25 Australian medtech and pharma companies are based in Victoria and nearly 60 per cent of Australia’s pharmaceutical exports are from Victoria.
Victoria’s life sciences professionals number more than 100,000 with the majority of the nation’s pharmaceutical life sciences professionals living in Victoria.
Victoria leads Australia in clinical trial capability, with the greatest number of trials underway of any State. Victoria’s strength in this area is reinforced by the co-location of research facilities with hospitals enabling accelerated development driven by insights from clinical investigators during early-stage clinical testing.
In May 2021, Victoria committed $400 million to establish the Australian Institute for Infectious Diseases, to be located beside the Doherty Institute, the first place in the world outside of China to decipher the genetic code for COVID-19. Victoria is already home to the Australian Government’s Australian Centre for Disease Preparedness operated by the CSIRO, and the Geelong Centre for Emerging Infectious Diseases.
International engagement and investment opportunities
mRNA Victoria is the lead government agency for domestic and international companies interested in participating in the development of the mRNA ecosystem in Victoria.
This includes pre and clinical stage research, manufacturing and supply chain partners, investors and therapeutic innovators in Australia and internationally to explore opportunities for partnerships with the Victorian Government to establish operations in Melbourne
Providing a detailed understanding of local RNA capability and opportunities for research and industry partnerships, mRNA Victoria offers clients a complete array of support, including:
- Identifying opportunities and building a business case
- Site selection assistance
- Business and stakeholder partnering
- Guidance with regulatory and compliance obligations
- Tailored financial support for business expansion and market entry
mRNA Victoria works through the Victorian Government’s 23 international offices, including a dedicated business development office in Boston, Massachusetts, to work with investors in markets around the world.
Research and industry development
Victoria is home to 22 globally recognised medical research institutes including the Doherty Institute, the Walter and Eliza Hall Institute of Medical Research, the Florey Institute, Peter MacCallum Cancer Centre, the Murdoch Children’s Research Institute and the Victorian Comprehensive Cancer Centre. Two of Victoria’s Universities, Melbourne and Monash are recognised as global top 20 leaders in medicine, and the Monash Institute of Pharmacy and Pharmaceutical Science is ranked at number two in the world.
mRNA Victoria is focused on supporting the development of IP in key areas of need to develop a strong pipeline of RNA research candidates and an ecosystem to support commercialisation and manufacturing.
Priority focus areas for support will be to enhance capacity across all aspects of the sector and build a strong pipeline of mRNA therapeutic candidates.
Applications are now open for the mRNA Victoria Research Acceleration Fund, which provides $2 million in grant support to accelerate RNA-based therapeutics research. Learn more and apply
mRNA Victoria will run grant programs throughout the year. Please check here regularly for updates on programs and opportunities when they become available or if you would like to be kept informed when grants become available, please email: firstname.lastname@example.org and include ‘Grants’ in the subject line.
To engage with mRNA Victoria or to sign up to our newsletter
Page last updated: 17 November 2021